Formycon AG (VIE:FYB)

Market Cap	328.72M -27.4%
Revenue (ttm)	52.28M -15.0%
Net Income	-56.90M
EPS	-3.22
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	19.08
Previous Close	18.74
Day's Range	18.68 - 19.08
52-Week Range	17.18 - 22.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About BNT

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 203
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: FYB

Financial Performance

In 2025, Formycon AG's revenue was 44.48 million, a decrease of -36.17% compared to the previous year's 69.67 million. Losses were -64.70 million, -48.52% less than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 8, 2026

Data Sources Report a data error